LSV Asset Management bought a new stake in C.R. Bard Inc. (NYSE:BCR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 525 shares of the company’s stock, valued at approximately $123,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lincoln National Corp increased its position in shares of C.R. Bard by 52.6% in the second quarter. Lincoln National Corp now owns 1,720 shares of the company’s stock worth $404,000 after buying an additional 593 shares during the period. Harfst & Associates Inc. increased its position in shares of C.R. Bard by 1.7% in the second quarter. Harfst & Associates Inc. now owns 2,350 shares of the company’s stock worth $552,000 after buying an additional 40 shares during the period. I.G. Investment Management LTD. increased its position in shares of C.R. Bard by 3.7% in the second quarter. I.G. Investment Management LTD. now owns 76,964 shares of the company’s stock worth $18,099,000 after buying an additional 2,743 shares during the period. Aviva PLC increased its position in shares of C.R. Bard by 192.9% in the second quarter. Aviva PLC now owns 110,686 shares of the company’s stock worth $26,028,000 after buying an additional 72,891 shares during the period. Finally, Mn Services Vermogensbeheer B.V. increased its position in C.R. Bard by 1.3% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 1,863 shares of the company’s stock worth $394,000 after buying an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Shares of C.R. Bard Inc. (NYSE:BCR) traded up 0.53% during trading on Tuesday, hitting $227.96. 525,601 shares of the company were exchanged. The company has a 50 day moving average of $220.12 and a 200-day moving average of $217.37. The stock has a market capitalization of $16.74 billion, a PE ratio of 53.01 and a beta of 0.57. C.R. Bard Inc. has a 1-year low of $172.21 and a 1-year high of $239.43.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.07. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The company earned $931.50 million during the quarter, compared to analyst estimates of $915.22 million. During the same quarter last year, the firm posted $2.27 earnings per share. The firm’s revenue was up 8.3% on a year-over-year basis. On average, analysts forecast that C.R. Bard Inc. will post $10.17 earnings per share for the current year.

A number of research firms recently issued reports on BCR. BMO Capital Markets reiterated a “hold” rating and set a $240.00 target price on shares of C.R. Bard in a research report on Wednesday, July 27th. Morgan Stanley reiterated a “hold” rating and set a $240.00 target price on shares of C.R. Bard in a research report on Thursday, July 28th. Deutsche Bank AG boosted their target price on shares of C.R. Bard from $234.00 to $240.00 and gave the company a “hold” rating in a research report on Wednesday, July 27th. Piper Jaffray Cos. reiterated a “buy” rating and set a $241.00 target price on shares of C.R. Bard in a research report on Tuesday, May 24th. Finally, Barclays PLC boosted their target price on shares of C.R. Bard from $224.00 to $235.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 27th. Thirteen research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $233.00.

In other C.R. Bard news, VP John A. Deford sold 7,928 shares of the firm’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $221.06, for a total transaction of $1,752,563.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.97% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard Inc. (NYSE:BCR).

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.